Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Dosage

8 evidence topics · 1 source

Recommended maintenance and maximum dosage

“Recommended maintenance dosage is 5 mg orally once daily. The dosage may be increased to a maximum of 15 mg once daily based on tolerability and clinical response. (2.1)” (opens the prescribing information at this quote)

Titration schedule
Treatment daysQuoted dosage
Days 1 to 4“0.25 mg once daily”
Days 5 to 8“0.5 mg once daily”
Days 9 to 12“0.75 mg once daily”
Days 13 to 16“1 mg once daily”
Days 17 to 20“1.5 mg once daily”
Days 21 to 24“2.25 mg once daily”
Days 25 to 40“3 mg once daily”
Maintenance, day 41 and thereafter“5 mg once daily”
Maximum dosage“15 mg once daily”
Dose escalation above 5 mg and titration interval

“If needed, based on tolerability and clinical response, the maintenance dose may be increased in increments of 5 mg approximately every 15 days to the maximum recommended daily dosage.” (opens the prescribing information at this quote)

“Dose and titration should be guided by tolerability and clinical response. If required, longer intervals between dose adjustment can be used.” (opens the prescribing information at this quote)

Dosage modification when initiating a CYP3A inhibitor during maintenance
Current maintenance dosageStrong CYP3A inhibitorModerate CYP3A inhibitor
5 mg once daily“5 mg every 7 days”“5 mg every 3 days”
10 mg once daily“10 mg every 7 days”“10 mg every 3 days”
15 mg once daily“15 mg every 7 days”“15 mg every 3 days”
CYP3A inhibitors during titration and after discontinuation

“Avoid concomitant use of strong or moderate CYP3A inhibitors during titration of JUVMO.” (opens the prescribing information at this quote)

“Upon discontinuation of the strong or moderate CYP3A inhibitor, resume the JUVMO maintenance dosage that was used prior to the initiation of the CYP3A inhibitor. Monitor patients for clinical response and tolerability.” (opens the prescribing information at this quote)

Dosage for patients already on long-term moderate CYP3A inducers
Treatment daysQuoted dosage
Days 1 to 4“0.25 mg twice daily”
Days 5 to 8“0.5 mg twice daily”
Days 9 to 12“0.75 mg twice daily”
Days 13 to 16“1 mg twice daily”
Days 17 to 20“1.5 mg twice daily”
Days 21 to 24“2.25 mg twice daily”
Days 25 to 40“3 mg twice daily”
Maintenance, day 41 and thereafter“5 mg twice daily”
Maximum dosage“45 mg daily”
Moderate CYP3A inducers started during maintenance, and strong CYP3A inducers

“Avoid concomitant use of strong CYP3A inducers during titration and maintenance of JUVMO.” (opens the prescribing information at this quote)

“Days 1 to 7 of concomitant use: continue the current maintenance dosage of JUVMO (5 mg, 10 mg, or 15 mg once daily).” (opens the prescribing information at this quote)

“Day 8 and thereafter during concomitant use: increase the frequency of the maintenance dosage of JUVMO to twice daily. If needed, based on clinical response and tolerability, the maintenance dosage can be increased to three times daily.” (opens the prescribing information at this quote)

“Upon discontinuation of moderate CYP3A inducers, gradually reduce the JUVMO dosage to once daily. Monitor patients for clinical response and tolerability.” (opens the prescribing information at this quote)

Renal and hepatic impairment dosing

“No clinically significant differences in pharmacokinetics of tavapadon were observed based on age (21 years to 79 years), sex, body weight (56 kg to 119 kg), race, severe renal impairment not requiring dialysis (eGFR < 30 mL/min estimated by CKD-EPI equation), mild hepatic impairment (Child-Pugh Class A), or moderate hepatic impairment (Child-Pugh Class B).” (opens the prescribing information at this quote)